Clinical trials: Atopic Dermatosis
Atopic Dermatitis
Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp)
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disease with a significant impact on patients' health-related quality of life.
- Trial name
- RAMpUp (NCT07741838)
- Volunteers
- 900 people
- Sponsor
- AbbVie
Atopic Dermatitis
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female.
- Trial name
- NCT07762833
- Testing
- Nemolizumab 30 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.
- Trial name
- NCT01652885
- Testing
- AN2728 Topical Ointment, 2%
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
- Trial name
- ROCKET-Orbit (NCT05633355)
- Testing
- Rocatinlimab
- Where
- 77 sites in United States, Argentina and 7 more
- Volunteers
- 187 people
- Sponsor
- Amgen
Atopic Dermatitis
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
- Trial name
- NCT04212169
- Testing
- MEDI3506
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Atopic Dermatitis, Healthy Participants
A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis
This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis.
- Trial name
- BYN-001-101 (NCT07746817)
- Testing
- BYN-001
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bionyra Pharma
Atopic Dermatitis
Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
A Multicenter, Randomized, Single-Blind, Phase Ⅱ Clinical Trial and Open Label Long-term Observation Study of ADSTEM Inj. to Evaluate the Safety and Efficacy in Patients with Moderate to Severe Subacute and Chronic Atopic…
- Trial name
- NCT04137562
- Testing
- ADSTEM Inj.
- Where
- 6 sites in South Korea
- Volunteers
- 118 people
- Sponsor
- EHL Bio Co., Ltd.
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EMOLLIENT CREAM IN SKIN OF COLOR
The aim of this study is to evaluate the efficacy and tolerance of a face and body emollient cream in individuals (infants, children, adults) with phototypes IV-VI presenting mild to moderate atopic dermatitis (study under…
- Trial name
- NCT07839897
- Testing
- Emollient cream RV4660B
- Where
- Brazil
- Volunteers
- 59 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- READY-AD (NCT07230860)
- Testing
- JNJ-95597528
- Where
- 62 sites in United States, Argentina and 7 more
- Volunteers
- 189 people
- Sponsor
- Janssen Research & Development, LLC
Dermatitis, Atopic
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts.
- Trial name
- NCT03750643
- Testing
- LY3454738
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study of Orally Administered IPG7236 in Healthy Adult Participants
The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult…
- Trial name
- NCT05288543
- Testing
- IPG7236- Single ascending dose, IPG7236- Multiple ascending dose
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Atopic Dermatitis
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study…
- Trial name
- NCT07003425
- Testing
- APG777
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 350 people
- Sponsor
- Apogee Therapeutics, Inc.
Atopic Dermatitis
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Flex-Up (NCT05507580)
- Testing
- Upadacitinib
- Where
- 106 sites in Australia, Belgium and 16 more
- Volunteers
- 461 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study of E6005 in Japanese Patients With Atopic Dermatitis
The safety and pharmacokinetics of topical application with E6005 ointment compared to vehicle will be evaluated in Japanese male patients with atopic dermatitis.
- Trial name
- NCT01179880
- Testing
- E6005
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.
This is a randomized, double-blind, placebo-controlled Phase Ib clinical trial evaluating the safety tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of GR2002 Injection in patients with moderate to severe…
- Trial name
- NCT06175143
- Testing
- GR2002 injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.
- Trial name
- NCT06767540
- Where
- 28 sites in China
- Volunteers
- 198 people
- Sponsor
- Akeso
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
The purpose of this study is to evaluate the safety and efficacy of product 0405 in pediatric subjects with Mild to Moderate Atopic Dermatitis.
- Trial name
- NCT02176538
- Testing
- Product 0405
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis (AD)
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S.
- Trial name
- NCT07411755
- Testing
- GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent®
- Where
- China
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Atopic Dermatitis
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
Phase 2 study of RPT193 in adults with atopic dermatitis
- Trial name
- NCT05399368
- Testing
- RPT193
- Where
- 59 sites in United States, Canada
- Volunteers
- 229 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies